Syneos Health has launched its Patient Voice Consortium. The Consortium is a cross-functional hub designed to share knowledge, resources, and relationships. These efforts seek to define best practices for gaining patient insights to pressure-test, problem-solve and co-create clinical trial design, communications, stakeholder education, access initiatives and launch strategies.
The Consortium builds on Syneos Health knowledge including patient journey mapping, behavioral science referenced in the Syneos Health subject matter authored book Why We Resist and ongoing DE&I efforts designed to expand access and diversity in clinical trials. The Consortium seeks to learn from the widest range of patient communities possible. Inclusive, transparent methodologies, rooted in shared purpose and bidirectional communications, will guide Consortium efforts.
For more information, click here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.